The deadly Nipah virus and others like it assemble themselves in a much more haphazard manner than previously thought, new UBC research has found. The discovery could allow scientists to develop more effective vaccines and rule out many approaches to fighting these viruses.
Chemistry professor Keng Chou and his team of researchers from UBC and Cornell University used a super-resolution microscope patented by UBC to observe whether viruses actually assemble in the way scientists have hypothesized.
"We looked at hundreds of images, and we couldn't find anything that supported the current model," said Chou. "For some of these deadly viruses, the replication process is actually not as complicated as some thought."
Nipah is an example of an "enveloped" virus, which gets its outer wrapping from the infected host cell, much like the viruses that cause influenza, rabies, measles and AIDS. Nipah can cause severe diseases and fatal brain swelling in both humans and animals. Yearly outbreaks in southeast Asia kill 40 to 90 per cent of those infected. In 2018, only two out of 19 people infected by Nipah in India survived an outbreak.
Nipah virus has three structural proteins: a matrix protein that provides structure, and two envelope proteins that enable the virus to attach and fuse with host cells. Scientists have believed that matrix proteins "recruit" envelope proteins, sending out some sort of signal so they can all join together on the cell membrane and become a functional virus. Researchers have tried to identify this signal in hopes of finding ways to disrupt the process.
However, Chou and his team observed that envelope proteins tend to be scattered randomly on the cell membrane. They now believe these proteins are picked up purely by chance when they are incorporated into a virus. This produces virus particles more quickly than previously envisioned, but many matrix proteins don't pick the envelope proteins up at all, and don't become functional viruses.
This observation has implications for vaccination, not just against Nipah but potentially against influenza, HIV and other enveloped viruses. Vaccines work by exposing a person to a small amount of modified virus or viral proteins, which rallies the body's natural defense. Currently, there is no Nipah vaccine approved for human use. One of the potential strategies under development is to use virus-like-particles, which are protein-based structures that mimic viruses, to stimulate immune response.
"If a vaccine contains a large percentage of virus-like particles that have only the matrix protein but not the envelope proteins, it won't trigger a strong immune response to the proteins that are most essential for helping a virus enter cells," said Qian Liu, a postdoctoral fellow in UBC's chemistry department who was lead author of the study. "Vaccines could be made more effective if we find a way to exclude those non-functional particles from the mix."
The study, supported by the Natural Sciences and Engineering Research Council of Canada and the Canada Foundation for Innovation, was published earlier this month in Nature Communications.
Source: University of British Colombia
Stay prepared and protected with Infection Control Today's newsletter, delivering essential updates, best practices, and expert insights for infection preventionists.
US Withdrawal From UNESCO Signals a Dangerous Step Back for Global Science
July 22nd 2025In a decision heavy with consequence and light on foresight, the US has once again chosen to walk away from UNESCO, leaving behind not just a seat at the table, but a legacy of global scientific leadership that now lies in question.
Pathogen Pulse: Facilities Need the SPD, Yersinia Enterocolitica Outbreak, and More
July 22nd 2025From unsterilized surgical tools in Colorado to a years-long methicillin-resistant Staphylococcus aureus (MRSA) outbreak in Virginia and a surging measles crisis in Canada, recent headlines reveal the fragile front lines of infection prevention and the high stakes when systems fail.
Telemedicine's Transformative Role in PPE Distribution and Sterile Equipment Management
July 22nd 2025In an era defined by digital transformation and post-pandemic urgency, telemedicine has evolved beyond virtual visits to become a vital infrastructure for delivering personal protective equipment (PPE) and managing sterile supplies. By enabling real-time forecasting, remote quality control, and equitable distribution, telemedicine is revolutionizing how health care systems protect both patients and providers.
Reducing Hidden Risks: Why Sharps Injuries Still Go Unreported
July 18th 2025Despite being a well-known occupational hazard, sharps injuries continue to occur in health care facilities and are often underreported, underestimated, and inadequately addressed. A recent interview with sharps safety advocate Amanda Heitman, BSN, RN, CNOR, a perioperative educational consultant, reveals why change is overdue and what new tools and guidance can help.
New Study Explores Oral Vancomycin to Prevent C difficile Recurrence, But Questions Remain
July 17th 2025A new clinical trial explores the use of low-dose oral vancomycin to prevent Clostridioides difficile recurrence in high-risk patients taking antibiotics. While the data suggest a possible benefit, the findings stop short of statistical significance and raise red flags about vancomycin-resistant Enterococcus (VRE), underscoring the delicate balance between prevention and antimicrobial stewardship.
What Lies Beneath: Why Borescopes Are Essential for Verifying Surgical Instrument Cleanliness
July 16th 2025Despite their smooth, polished exteriors, surgical instruments often harbor dangerous contaminants deep inside their lumens. At the HSPA25 and APIC25 conferences, Cori L. Ofstead, MSPH, and her colleagues revealed why borescopes are an indispensable tool for sterile processing teams, offering the only reliable way to verify internal cleanliness and improve sterile processing effectiveness to prevent patient harm.